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Abstract
Purpose: The purpose of this study is to analyze the dosimetric parameters ofthree dimensional conformal radiotherapy (3DCRT), intensity modulatedradiotherapy (IMRT) with seven and nine fields (7F-IMRT, 9F-IMRT) in selectedadvanced stage cervical cancer cases.Methods: Fifteen cases of cervical cancer (IIBto IIIB) were selected for retrospective analysis. All the cases were previouslytreated with 3DCRT technique with prescribed dose of 50 Gy in 25 fractions.  Forthis study, plans with seven fields IMRT and nine fields IMRT were generated for allpatients following Radiation Therapy Oncology Group (RTOG) guidelines. Theplans were compared on the basis of planning target volume (PTV) coverage (doseto 1%, 5%, 95% and 99% of target), maximum dose and mean dose to organs atrisk (OARs) and also doses at different volumes of OARs. Apart from this,uniformity index (UI), homogeneity index (HI), conformity index (CI) and dosespillage index (R50%) were also calculated with respect to PTV coverage. Results:The average dose value of PTV coverage for all three techniques were comparableand all the DVH indices for 7field IMRT (UI (1.04±0.01), HI (0.07 ±0.02), CI(0.75±0.03) and R50% (4.47±0.36)) were better than 3DCRT and 9F-IMRTtechniques. All OAR doses were significantly reduced in 7F- IMRT compared to3DCRT and 9F- IMRT. The target volumes ranged from 769.2 ml to 1375.6 ml withaverage target volume of 1071.9 ml (SD: 205.38 ml). Conclusion: This studyshowed that significant dose reduction to OARs could be achieved with seven fieldIMRT plans by maintaining the PTV coverage compared to 3DCRT or 9F- IMRT fortreating cervical cancer in advanced stages particularly from IIB to IIIB.
Keywords: Three dimensional conformal radiotherapy, Intensity modulatedradiotherapy, Organs at risk, Uniformity index, Conformity index, Homogeneityindex, Dose spillage index.
1. IntroductionThe most common cancer in women is carcinoma ofcervix.1 InWorldwide, carcinoma of cervix is the fourthmost common for females and the seventh mostcommon cancer overall.2 The Radiation treatment forcervical cancer includes combination of teletherapy andbrachytherapy. There are much more advancements inthe radiation treatment planning. In early 1990s, threedimensional conformal radiotherapy using CT images
was the standard method to deliver radiation.Subsequently, more advanced technology IMRT wasinnovated in the late 1990s. In IMRT, the intensity ofeach beam is modified with the help of multileafcollimators (MLC) using inverse planning algorithms totreat the entire tumor while sparing critical structures.IMRT is the basis for all the new techniques like IGRT,VMAT and other modern techniques(SRS and SRT). Anumber of studies showed the benefit of IMRT overconventional external beam therapy.3-5 Apart from
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IMRT, cancer of cervix treated with other moderntechniques were also reported. Bloemers et al.6 showedthat for the treatment of locally advanced vulvar cancer,IMRT was attractive option for dose escalation studies.The IMRT with 6 MV photon beam was a better choiceinstead of 15 MV photons for treatment of carcinoma ofcervix as proposed by Tyagi et al.7 Despite treatinglarger volume with four field box technique, volumetricarc therapy was showing better PTV coverage withminimum dose to OARs8. Erpolat et al.9 showedthat IMRT planning reduced irradiated bone marrowvolumes compared to 3DCRT planning after receivingconcurrent chemotherapy (cisplatin). However, nodifference between the two techniques was observed interms of acute and chronic hematologic toxicity. Avinash
et al.10 also reported reduction in bone marrow dosewhile treating with IMRT with concurrent chemotherapy(platinum based) compared to 3DCRT. Mounessi et al.11reported better conformity around PTV and sparing ofOARs with IMRT compared to 3DCRT. Khosla et al.12concluded that IMRT showed superior plans withrespect to target coverage, homogeneity, conformitywith sparing of OARs. In addition, they conclude thatIMRT reduces NTCP while maintaining TCP. Chang et
al.13showed the dosimetric advantage of IMRT in thecontext of IGRT where internal movement of tumor wasmonitored during fractionated radiotherapy. Pathak et
al.14 concluded that each IMRT plan must be evaluatedand compared by using the S-index score because,S-index is directly related to the biological effects(equivalent uniform dose). Mahmoud et al.15 compared 5field conformal technique with 8 field IMRT andconcluded that IMRT showed better results with respectto sparing of OARs at different volumes, while the PTVwas adequately covered. Cozzi et al.16 showed advantageof rapid arc over IMRT: "For rectum the mean dose wasreduced by about 6 Gy (10 Gy for the rectum fraction notincluded in the PTV). Similar trends were observed forthe various dose levels with reductions ranging fromapproximately 3 to 14.4 Gy. For the bladder, Rapid Arcallowed a reduction of mean dose ranging fromapproximately 4 to 6 Gy and a reduction fromapproximately 3 to 9 Gy with respect to IMRT. Similartrends but with smaller absolute differences wereobserved for the small bowel and left and right femoralheads." Like this, many authors17-20also, showedadvantages of IMRT for cervix as well as other sites also.In the present study, as we have a database of treatedadvanced cases of cervical cancer, an independentretrospective investigation of the benefit of IMRT31 wasattempted. Specifically our goal was to compare the7F-IMRT with 9F-IMRT and show their relative meritswith respect to the 3DCRT techniques that was used totreat these patients. The dose coverage to target and thedose spillage to different organs at risk were evaluatedusing DVH analysis. The results were compared withthose reported by other investigators.11, 12
2. Methods and MaterialsA 6 MV linear accelerator, Clinac 600C (Varian MedicalSystems, Palo Alto, CA) having 40 pair MLC, each pairprojecting 1cm width at isocenter was used for thedelivery of radiation treatments. Fifteen cases of cervicalcancer (previously treated with 3DCRT technique) weretaken for a retrospective study by re-planning with 7Fields and 9 Fields IMRT. For all the cases, prescribeddose of 50 Gy was given in 25 fractions (2 Gy/fraction).Thermoplastic sheet (Orfit Industries n.v., Vosveld 9A,2110 Wijnegem, Belgium) was used for immobilizing thepatients. A Philips (16 slice, 85cm diameter, big bore) CTscanner was utilized for imaging of the patients and theCT images of 3 mm slice thickness were acquired insupine position. The CT scans were transferred to theEclipse treatment panning system (TPS), version 13.6(Varian Medical Systems, Palo Alto, CA). The gross targetvolume (GTV), clinical target volume (CTV), planningtarget volume (PTV) and organs at risk (OARs) werecontoured on the CT images by qualified radiationoncologist following the guidelines of InternationalCommission on Radiation Units and Measurements(ICRU) report 83.21 All the OARs were overlapped withPTV and were not cropped from the PTV. So, largevolumes of OARs were included with PTV. As these caseswere in advanced stage; the sizes of volumes of PTVwere found to vary from 769. 2 ml to 1375.6 ml with amean value of 1071.93 ml. Initially, the 3DCRT (gantryangles 00,900, 1800 and 2700) was done for all 15patients. The beam energy of 6MV, beam weightings andMLC leaf positions were optimized by forward planningto reduce the doses to critical organs and betterhomogeneous dose distribution in the PTV. Followingthe 3DCRT plan, dynamic 7F- IMRT and 9F- IMRT planswere created using the beam energy of 6MV at gantryangles of 00, 350, 700, 1300, 2300, 2900 & 3250 for7F-IMRT and at gantry angles of 00, 350, 750, 1100, 1450,2150, 2300, 2500 & 2900 for 9F-IMRT. For dosecalculation, AAA algorithm was used with a grid size of2.5 mm. An annular ring was drawn around the PTVwith 5 mm and 3 cm margins and a dose constraint forIMRT was defined such that 10% dose fall off per cm.This type of template was created and applied to all the15 patient plans. In addition, the achievable constraintswere changed to obtain possible minimum dose tocritical organs without compromising the PTV coverageof at least 95% of dose to 95% of PTV volume.Comparison of dose distribution in PTV and organs atrisk were evaluated for all the three techniques.
2.1 Plan analysis based on DVH parameters:The 3DCRT, 7F-IMRT and 9F-IMRT plans were evaluatedand compared based on following dosimetricparameters.(a) The Conformity Index (CI) was evaluated by theformula22 below as defined by other investigators.22, 23
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CI = { TV95/TV}{TV95/V95}where TV95 is the volume of target covered by 95%isodose line, TV is the total target volume and V95 is thevolume of tissue covered by the 95% isodose line. Thevalue of CI varies between 0 to 1 and value close to unityis indicative of better conformity of dose to the PTV.(b) The Uniformity Index (UI) was evaluated24 asdefined in the literature24,25 byUI =D5/D95where D5 and D95 are the minimum doses to 5% and95% volume of PTV.The value of UI close to 1 signifies better uniformity ofPTV dose.(c) The Homogeneity Index (HI) was evaluated26 asdefined previously by many authors.26-28HI = (D1-D99)/ Prescribed Dosewhere D1 and D99 are doses to 1% and 99% of PTVThe smaller the value of HI more is thehomogeneous distribution in PTV.(d) The Dose Spillage Index (R50%) was evaluated29as defined by investigators29, 30by
R50% =50% Isodose Volume/ PTV volume.The lower the R50% ratio indicates greater dose fall offand better dose conformity around the PTV.Statistical analyses of the data sets were done betweenthe three techniques. The p-values were calculated usingt-test. When p value is less than 0.05, the differencebetween the any two treatment techniques wasconsidered as significant. The value of p closer to zeroimplies that the statistical significance is more betweentwo compared techniques.
3. Results and DiscussionThe comparison of detailed results for three techniques(3DCRT, 7F-IMRT and 9F-IMRT) are given in Table1 forPTV coverage and in Table 2 for OAR doses. Percentdifference among the three techniques is shown in Table3. Table 4 shows the average values of DVH indices forthe three techniques. Figure1 shows the comparison oftypical colour wash dose display between 3DCRT and7F-IMRT fields for a representative patient. The DVHcomparison of PTV coverage and OAR doses for threetechniques are given in Figures (2-4).
Figure 1: Typical comparison of color wash display for 3DCRT and 7F-IMRT techniques.
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Figure 2: DVH comparison of 3DCRT(Thick lines) and 7F-IMRT(Thin lines) techniques for all structures.
Figure 3: DVH comparison of 3DCRT(Thick lines) and 9F-IMRT(Thin lines) techniques for all structures.
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Table 1: Summary of average values for PTV coverage for 3 techniques (3DCRT, 7F-IMRT & 9F-IMRT).3D-CRT 7F-IMRT 9F-IMRT p-valuePTV Mean (%) SD Mean (%) SD Mean (%) SD 3D vs.7F 3D vs. 9F 7F vs. 9FD1% 106.0 0.7 105.0 1.4 105.3 1.0 0.02 0.05 0.42D5% 105.1 0.5 104.1 1.3 104.0 1.0 0.01 0 0.96D95% 99.3 1.1 99.4 1.3 97.9 1.6 0.8 0.01 0.01D99% 96.3 2.1 97.4 1.8 95.2 2.2 0.14 0.14 0TV (95%) 99.4 0.6 99.8 0.4 98.7 1.1 0.05 0.05 0TV95(ml) 1065.9 211.7 1069.0 209.2 1055.5 202.4 0.97 0.89 0.86V95(ml) 2625.1 473.8 1407.5 254.9 1421.5 238.0 0 0 0.88Dmean% 102.4 0.7 102.0 1.2 101.4 1.2 0.23 0.01 0.17Dmax% 106.9 0.9 107.8 1.8 108.3 1.0 0.09 0 0.35Dmin% 82.9 7.3 86.0 7.7 79.1 8.3 0.27 0.19 0.03
Table 2: Summary of OAR doses for three techniques (3DCRT, 7F-IMRT, and 9F-IMRT).OAR 3D 7F 9F p-valueMean(Gy) SD Mean(Gy) SD Mean(Gy) SD 3D vs. 7F 3D vs. 9F 7F vs. 9FBladder( max) 53.1 0.8 53.1 1.2 54.4 1.4 0.9 0 0.01Bladder( mean) 49.3 1.3 44.6 4.7 45.6 3.6 0 0 0.53Bladder (D50%) 51.2 0.6 46.7 3.0 47.9 2.7 0 0 0.24Rectum( max) 51.2 0.2 52.8 0.6 53.5 0.2 0 0 0Rectum( mean) 46.6 2.9 43.8 5.9 44.4 5.2 0.11 0.17 0.75Rectum (D35%) 50.9 0.4 49.6 1.3 50.4 1.5 0 0.25 0.13Bowel (max) 53.2 0.2 53.6 1.2 53.8 1.5 0.22 0.14 0.68Bowel (mean) 25.8 5.7 22.6 4.4 22.9 4.3 0.1 0.12 0.89Bowel(D100%) 5.1 9.0 4.9 7.5 4.9 6.4 0.94 0.93 1Bowel(D75%) 17.9 16.2 13.7 13.3 15.0 12.7 0.44 0.59 0.79Bowel (D50%) 33.6 11.5 27.0 9.5 28.6 9.0 0.1 0.2 0.64Bowel(D25%) 44.3 8.7 39.2 8.7 41.9 8.2 0.11 0.44 0.37RT Femoral ( max) 51.9 0.7 47.0 2.1 50.1 3.8 0 0.09 0.01RT Femoral (mean) 29.4 9.9 16.2 3.5 21.2 6.6 0 0.01 0.02RT. Femoral (D10%) 49.7 2.8 40.6 4.4 42.3 4.7 0 0 0.32RT Femoral (D50%) 30.9 8.1 18.1 9.1 21.0 8.4 0 0 0.37RT Femoral (D100%) 7.8 7.9 4.0 5.1 5.3 6.3 0.13 0.35 0.53Lt.Femoral (max) 51.3 0.1 50.4 0.6 51.5 2.6 0 0.81 0.14Lt.Femoral (mean) 29.1 4.8 18.4 2.8 23.8 5.9 0 0.01 0Lt.Femoral (D10%) 45.8 10.2 40.0 5.6 42.1 4.4 0.07 0.22 0.26Lt.Femoral (D50%) 29.4 4.2 18.7 9.4 21.2 7.0 0 0 0.42Lt.Femoral (D100%) 8.6 8.5 3.7 4.3 4.8 5.5 0.06 0.15 0.55
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Figure 4: DVH comparison of 7F-IMRT(Thick line) and 9F-IMRT(Thin Line) techniques for PTV coverage and OAR doses
Table 3: Percentage of variation of OAR doses for three techniques.OAR 3DCRT 7F 9F Difference (%)(Gy) (Gy) (Gy) 3D vs. 7F 3D vs. 9F 7F vs. 9FBladder (max) 53.1 53.1 54.4 -0.1 -2.5 -2.5Bladder (mean) 49.3 44.6 45.6 9.6 7.6 -2.2Bladder (D50%) 51.2 46.7 47.9 8.8 6.3 -2.7Rectum( max) 51.2 52.8 53.5 -3.0 -4.4 -1.3Rectum( mean) 46.6 43.8 44.4 6.1 4.7 -1.5Rectum (D35%) 50.9 49.6 50.4 2.6 1.0 -1.7Bowel (max) 53.2 53.6 53.8 -0.8 -1.1 -0.4Bowel( mean) 25.8 22.6 22.9 12.3 11.4 -1.0Bowel (D100%) 5.1 4.9 4.9 4.9 5.1 0.2Bowel (D75%) 17.9 13.7 15.0 23.5 16.3 -9.5Bowel (D50%) 33.6 27.0 28.6 19.6 14.8 -5.9Bowel (D25%) 44.3 39.2 41.9 11.7 5.4 -7.1RT Femoral Head( max) 51.9 47.0 50.1 9.3 3.5 -6.4RT Femoral Head( mean) 29.4 16.2 21.2 44.9 28.0 -30.7RT Femoral Head (D10%) 49.7 40.6 42.3 18.3 14.9 -4.1RT Femoral Head ( D50%) 30.9 18.1 21.0 41.5 32.1 -16.0RT Femoral Head (D100%) 7.8 4.0 5.3 48.9 31.9 -33.3LT.Femoral Head( max) 51.3 50.4 51.5 1.7 -0.3 -2.1LT.Femoral Head( mean) 29.1 18.4 23.8 37.0 18.2 -29.8LT.Femoral Head (D10%) 45.8 40.0 42.1 12.7 8.0 -5.3LT.Femoral Head (D50%) 29.4 18.7 21.2 36.4 27.9 -13.4LT.Femoral Head (D100%) 8.6 3.7 4.8 57.3 44.9 -29.1
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Table 4: Average values of calculated DVH indices for three techniques.
In the present study, as can be seen from Table 4, it wasfound that the PTV coverage with 3DCRT, 7F-IMRT wasbetter compared to 9F-IMRT. This is also evident bycomparing DVH graphs for PTV and OARs shown inFigures (2-4). All the DVH indices are showing thefavorable results for 7F-IMRT (p-value 0.00) over3DCRT technique. Again, comparison of 9 fields IMRTover 7 fields IMRT, the difference is observed only incases of conformity index and dose spillage index. Byincreasing the number of fields from 7 fields to 9 fields,no advantage was observed for PTV coverage as well asreduction in dose to OARs. In addition, doses to 1%,95%, 99%, maximum, mean, minimum dose of PTV,maximum, mean and doses at different volumes of OARsare comparable in all three techniques. This is evidentfrom Tables (1-3). Thus, increase in number of fields isnot helpful. It should be noted that optimum number offields in IMRT depends on target and OAR volumes. Ingeneral, small target volumes could benefit frommultiple fields and vice versa. In the current study, theadvantage of IMRT over 3DCRT in case of advancedstage (IIB to IIIB) carcinoma of cervix has beendemonstrated. The percentage reduction in OAR doseswas less when compared to other studies.11, 12, 15, 16 Thisis due to large volumes of OARs overlapping with PTV.With 7 fields IMRT, the reduction in OAR dosescompared to 3DCRT, were as follows. The reduction inmean dose for bladder, rectum and bowel are 9.6%,6.1% and 12.3% respectively. The mean doses of rightand left femoral heads were reduced by 44.9% and 37%respectively. There was also a less significant reductionin OAR doses with 9 fields IMRT.
4. ConclusionIMRT plans reduce the dose to OARs thereby decreasethe toxicity of normal organs without compromising theconformity and homogeneity of dose distribution in thetarget volume compared to conventional 3DCRTtechniques. For the target volumes in the current studyranging from 769.2 ml to 1375.6 ml (average targetvolume of 1071.9 ml), it was found that seven field IMRTgave the optimum dose coverage for target as well asminimal doses to OARs. Even for advanced cervicalcancers, IMRT could be possible with optimal number offields depending upon tumor size.
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